A new survival score for patients with brain metastases who received whole-brain radiotherapy (WBRT) alone

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064203%3A_____%2F13%3A10294183" target="_blank" >RIV/00064203:_____/13:10294183 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11130/13:10294183

Výsledek na webu

<a href="http://dx.doi.org/10.1016/j.radonc.2013.06.009" target="_blank" >http://dx.doi.org/10.1016/j.radonc.2013.06.009</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.radonc.2013.06.009" target="_blank" >10.1016/j.radonc.2013.06.009</a>

Jazyk výsledku

angličtina

Název v původním jazyce

A new survival score for patients with brain metastases who received whole-brain radiotherapy (WBRT) alone

Popis výsledku v původním jazyce

Background and purpose: Survival scores for patients with brain metastasis exist. However, the treatment regimens used to create these scores were heterogeneous. This study aimed to develop and validate a survival score in homogeneously treated patients.Materials and methods: Eight-hundred-and-eighty-two patients receiving 10 x 3 Gy of WBRT alone were randomly assigned to a test group (N = 441) or a validation group (N = 441). In the multivariate analysis of the test group, age, performance status, extracranial metastasis, and systemic treatment prior to WBRT were independent predictors of survival. The score for each factor was determined by dividing the 6-month survival rate (in %) by 10. Scores were summed and total scores ranged from 6 to 19 points. Patients were divided into four prognostic groups. Results: The 6-month survival rates were 4% for 6-9 points, 29% for 10-14 points, 62% for 15-17 points, and 93% for 17-18 points (p < 0.001) in the test group. The survival rates were

Název v anglickém jazyce

A new survival score for patients with brain metastases who received whole-brain radiotherapy (WBRT) alone

Popis výsledku anglicky

Background and purpose: Survival scores for patients with brain metastasis exist. However, the treatment regimens used to create these scores were heterogeneous. This study aimed to develop and validate a survival score in homogeneously treated patients.Materials and methods: Eight-hundred-and-eighty-two patients receiving 10 x 3 Gy of WBRT alone were randomly assigned to a test group (N = 441) or a validation group (N = 441). In the multivariate analysis of the test group, age, performance status, extracranial metastasis, and systemic treatment prior to WBRT were independent predictors of survival. The score for each factor was determined by dividing the 6-month survival rate (in %) by 10. Scores were summed and total scores ranged from 6 to 19 points. Patients were divided into four prognostic groups. Results: The 6-month survival rates were 4% for 6-9 points, 29% for 10-14 points, 62% for 15-17 points, and 93% for 17-18 points (p < 0.001) in the test group. The survival rates were

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2013

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Radiotherapy and Oncology

ISSN

0167-8140

e-ISSN

—

Svazek periodika

108

Číslo periodika v rámci svazku

1

Stát vydavatele periodika

NL - Nizozemsko

Počet stran výsledku

5

Strana od-do

123-127

Kód UT WoS článku

000324155900019

EID výsledku v databázi Scopus

—